Ramsay et al., 1999 - Google Patents
Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunityRamsay et al., 1999
- Document ID
- 4582698599751314991
- Author
- Ramsay A
- Kent S
- Strugnell R
- Suhrbier A
- Thomson S
- Ramshaw I
- Raima A
- Kent S
- Strugnell R
- Suhrbicr A
- Thomson S
- Ramshaw I
- Publication year
- Publication venue
- Immunological reviews
External Links
Snippet
In this article, we describe several novel genetic vaccination strategies designed to facilitate the development of different types of immune responses. These include: the consecutive use of DNA and fowlpoxvirus vectors in “prime‐boost” strategies which induce greatly enhanced …
- 238000002255 vaccination 0 title abstract description 84
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ramsay et al. | Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity | |
| Chattergoon et al. | Genetic immunization: a new era in vaccines and immune therapeutics | |
| Cohen et al. | Modulating the immune response to genetic immunization | |
| JP6356653B2 (en) | Improved vaccine and method for using the same | |
| Hanke et al. | Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS | |
| AU699044B2 (en) | Induction of cytotoxic T-lymphocyte responses | |
| Deml et al. | Recombinant human immunodeficiency Pr55gagVirus-like particles presenting chimeric envelope glycoproteins induce cytotoxic t-cells and neutralizing antibodies | |
| Dale et al. | Chimeric human papilloma virus–simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques | |
| Schirmbeck et al. | Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens | |
| Sykes et al. | Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses | |
| Nehete et al. | Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model | |
| Malkevitch et al. | A call for replicating vector prime-protein boost strategies in HIV vaccine design | |
| JP2004518443A (en) | Recombinant poxvirus for chimeric proteins of human immunodeficiency virus | |
| Belyakov et al. | Mucosal AIDS vaccines: current status and future directions | |
| Barouch et al. | DNA vaccination for HIV-1 and SIV | |
| Liu et al. | using HIV-Gene-Containing DNA | |
| Hurwitz et al. | HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail | |
| Jiang et al. | Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector | |
| Young et al. | Elicitation of immunity to HIV type 1 Gag is determined by Gag structure | |
| Choi et al. | Enhancement of DNA vaccine-induced immune responses by influenza virus NP gene | |
| Sandberg et al. | Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization | |
| Couillin et al. | DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses | |
| Paterson | Rational approaches to immune regulation | |
| Adams et al. | Use of new vectors for the development of vaccines | |
| JP2017512499A (en) | Mosaic HIV-1 sequences and uses thereof |